2018 American Transplant Congress
Urinary Proteomic Biomarkers for Prediction of Chronic Antibody-Mediated Rejection in Kidney Transplant Recipients
Background: Chronic antibody-mediated rejection (CAMR) is a challenging issue associated with allograft loss in kidney transplant recipients (KTRs) undergoing long-term follow-up. Changes in the urinary…2018 American Transplant Congress
The Impact of Conversion from Immediate Release Twice-Daily Tacrolimus (Prograf®) to Once-Daily Extended Release Tacrolimus (Envarsus®) in Liver Transplant Recipients
The safety and efficacy of substitution with a novel once-daily extended-release tacrolimus (LCPT;Envarsus®)to immediate-release tacrolimus (IR-Tac, Prograf®) twice daily in liver transplant patients have not…2018 American Transplant Congress
Clinical Significance of Isolated v-Lesions in Kidney Transplantation
Background: Arteritis without significant tubulo-interstitial inflammation (v1-3, but i≤1 and t≤1) is referred by the 10th Banff conference as 'isolated v-lesions'. The clinical significance of…2018 American Transplant Congress
Effect of Belatacept on Late Acute Rejection Episodes and Graft Loss in Young Adults between the Ages of 18-24 Years: Post-Hoc Analysis of BENEFIT Study
Nephrology, Children National Health System, Washington, DC.
Background: Recent data suggests higher incidence of late acute rejection (LAR) in young adults (18-24 years of age) causing graft loss just like adolescents due…2018 American Transplant Congress
Allogeneic Mesenchymal Stem Cells as Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial
Background: Delayed graft function (DGF) and acute rejection lead to adverse effects on graft outcomes. Optimal induction intervention should include both renal structure injury repair…2018 American Transplant Congress
Donor-Derived Cell-Free DNA Identifies Antibody-Mediated Rejection with Graft Injury in DSA-Positive Kidney Transplant Recipients
Purpose: Donor-derived cell-free DNA (dd-cfDNA) discriminates active rejection in kidney transplant patients. Donor-specific antibodies (DSA) to HLA antigens are associated with risk of antibody-mediated rejection…2018 American Transplant Congress
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)
Background. Antibody-mediated rejection (ABMR) is a leading cause of long-term kidney transplant loss. Optimal treatment of late ABMR is unclear, and our current knowledge is…2018 American Transplant Congress
Dual Inhibition of PI3K and mTORC2 Causes ERK Hyperactivation Induced by HLA-II Antibody in Human Endothelium
Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA.
Background: Endothelial cells (EC) line the inner surface of blood vessels and serve as the interface between recipient circulating blood and the donor allograft. Transplant…2018 American Transplant Congress
The Risk Factors of Acute Rejection in Patients with BK Nephropathy after the Reduction of Immunosuppression
Background: BK nephropathy (BKN) affects graft function and increases the risk of graft failure. The reduction of immunosuppression is the main treatment for BKN. However,…2018 American Transplant Congress
The Inhibitory Effect of Plasma on Activation of Lymphocytes from Kidney Transplants is Significantly More Severe in Tacrolimus Based Regimen: What Implications for Plasma Exchange Role in Anti-Rejection Therapy?
Background:Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented. However, trial…
- « Previous Page
- 1
- …
- 92
- 93
- 94
- 95
- 96
- …
- 172
- Next Page »